{"preliminary_commentary":{"by_channel":{"youtube":4,"podcast":4,"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01494662\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["neratinib","capecitabine"],["neratinib"],["neratinib","ado-trastuzumab emtansine"]],"indication":"HER2-positive breast cancer with brain metastases","name":"TBCRC 022","nct_id":"NCT01494662","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tbcrc-022-nct01494662. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients With Progressive Brain Metastases\n\nIntervention: HKI-272 (Neratinib)340 mg orally, once daily.","label":"Cohort 1","type":"ACTIVE_COMPARATOR"},{"description":"Patients Who Are Candidates For Craniotomy.\n\nIntervention: HKI-272 (Neratinib) 240 mg orally, once daily.\n\nSurgical resection (biopsy).\n\nNeratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.","label":"Cohort 2","type":"ACTIVE_COMPARATOR"},{"description":"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.\n\nCohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.","label":"Cohort 3a/3b","type":"ACTIVE_COMPARATOR"},{"description":"Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.\n\nCohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.\n\nCohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.","label":"Cohort 4a/4b/4c","type":"ACTIVE_COMPARATOR"}],"collaborators":["Translational Breast Cancer Research Consortium","Puma Biotechnology, Inc."],"completion_date":{"date":"2024-04-19","type":"ACTUAL"},"conditions":["Breast Cancer"],"enrollment":{"count":140,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"HKI-272","otherNames":["Neratinib"],"type":"DRUG"},{"name":"Surgical Resection","otherNames":["Biopsy"],"type":"PROCEDURE"},{"name":"Capecitabine","otherNames":["Xeloda"],"type":"DRUG"},{"name":"HKI-272","otherNames":["Neratinib"],"type":"DRUG"},{"name":"Ado-Trastuzumab Emtansine","otherNames":["T-DM1"],"type":"DRUG"}],"last_update":"2026-01-23","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate Per Composite Response Criteria","timeFrame":"2 years"},{"measure":"Objective Response Rate Per RANO-BM Criteria","timeFrame":"2 years"}],"references":[{"citation":"Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (TBCRC). Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 Apr;20(2):145-151.e2. doi: 10.1016/j.clbc.2019.07.011. Epub 2019 Aug 22.","pmid":"31558424","type":"DERIVED"},{"citation":"Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.","pmid":"30860945","type":"DERIVED"},{"citation":"Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.","pmid":"26834058","type":"DERIVED"}],"start_date":{"date":"2012-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","url":"https://clinicaltrials.gov/study/NCT01494662"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tbcrc-022-nct01494662"}